The tirzepatide amino acid sequence and what it tells us about the medicine

What the 39-amino-acid sequence actually does inside the body

A peptide's amino acid sequence is its instruction manual. Each position in tirzepatide's 39-residue chain determines how the finished molecule folds, which receptors it binds, and with what affinity. If you want to go deeper, our dedicated page on the tirzepatide peptide sequence walks through each structural feature in detail, including the substitutions that confer GLP-1 receptor binding and the C20 fatty-diacid chain attached via a small linker at the C-terminus. That lipid tail is what anchors tirzepatide to albumin in the bloodstream, slowing its clearance and producing the weekly dosing window that makes Mounjaro practical for patients.

The GIP-like core of the sequence binds GIP receptors on fat cells and pancreatic beta cells. The modified regions engage GLP-1 receptors in the gut, pancreas, and brain. Activating both pathways together slows gastric emptying, reduces appetite signalling in the hypothalamus, and improves insulin secretion in a glucose-dependent way — meaning the insulin response tracks blood sugar rather than running continuously. More on how tirzepatide works as a medicine is covered in our main tirzepatide guide. The NHS's patient-level information on tirzepatide also explains the mechanism in accessible terms, and is worth reading alongside any clinical overview.

What the sequence does not do is make tirzepatide interchangeable with simpler peptides. Even small modifications to the amino acid order would alter receptor affinity substantially. This is one reason why counterfeit versions carrying an incorrect or degraded sequence present a genuine safety hazard: the molecule you inject is not the molecule that was tested.

How tirzepatide's sequence compares with semaglutide's, and why the difference shows up in trial results

Semaglutide is a 31-amino-acid peptide derived from human GLP-7-36 amide, modified at a handful of positions and carrying its own fatty-acid extension. It binds only the GLP-1 receptor. Tirzepatide's sequence is eight residues longer and structurally distinct enough that it was developed from GIP rather than GLP-1 as its scaffold.

That structural difference translates into measurable outcomes. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, participants taking tirzepatide 15 mg achieved an average body-weight reduction of around 20–21% over 72 weeks alongside a reduced-calorie diet and increased activity. In the SURMOUNT-5 head-to-head trial (also published in the NEJM in 2025), tirzepatide produced greater average weight reduction than semaglutide 2.4 mg over 72 weeks in adults with obesity and without diabetes. NICE cited these data in its technology appraisal of tirzepatide (TA1026), published in December 2024, when recommending it for adults with BMI 35 or above and at least one weight-related comorbidity.

The head-to-head advantage is attributed, at least in part, to dual-receptor activation. GIP agonism appears to enhance the appetite-suppression produced by GLP-1 signalling rather than simply duplicating it. Whether that synergy also reduces the nausea associated with pure GLP-1 activation is still being studied; tirzepatide's GI side-effect profile is broadly similar to semaglutide's, though some trial analyses suggest lower rates of nausea at comparable weight-loss effect. Comparing Mounjaro with other options goes into this in more depth.

What the sequence means for the medicine you actually receive

In clinical use, tirzepatide is dispensed as Mounjaro, a pre-filled KwikPen delivering a precise dose of the synthetic peptide in a stabilised formulation. The pen contains four weekly doses. Treatment starts at 2.5 mg (a dose chosen for tolerability as the body adjusts) and is titrated upward by the prescriber, typically in four-week steps, through strengths of 5, 7.5, 10, 12.5, and 15 mg; our page on Mounjaro frequency explains how this titration schedule works and what to expect at each stage.

Storage matters because peptides degrade. The pen is refrigerated at 2–8°C; the patient information leaflet and the Mounjaro SmPC on the eMC give the exact room-temperature window for travel. When your order arrives via DPD (tracked, in plain unbranded packaging) the pen will have been dispatched cold-chain from our GPhC-registered pharmacy.

If you are researching the peptide sequence because you have seen products described as tirzepatide sold outside a licensed pharmacy, the structural specificity of the molecule is exactly why that matters. The amino acid sequence must be correct and the formulation must be stable for the medicine to be what it claims. Our Mounjaro overview covers the UK supply chain and what a legitimate dispensing route looks like in practice.

For context on what private treatment typically costs, our Mounjaro pricing page explains how the market is structured and what a transparent single price should include. Tirzepatide is a prescription-only medicine; suitability is always a clinical decision. Speak to our prescribers if you would like a same-day clinical review.